Acknowledgments

This report was compiled through the combined efforts of many individuals in the District of Columbia Department of Health’s HIV/AIDS, Hepatitis, STD, and Tuberculosis Administration, with contribution from the Milken Institute School of Public Health at George Washington University. This report would not have been possible without the hard work, dedication, and contribution of health care providers, community groups, researchers, and members of the community.

Muriel Bowser, Mayor
Rashad M. Young, City Administrator
LaQuandra S. Nesbitt, MD, MPH, Director, Department of Health
Michael Kharfen, Senior Deputy Director

With special thanks to:
- Strategic Information Division
- STD/TB Control Division
- GWU Milken Institute School of Public Health

The Annual Epidemiology & Surveillance Report is compiled by the Strategic Information Division. To request additional data or aid in interpreting the data herein, contact:

Strategic Information Division
HIV/AIDS, Hepatitis, STD, and TB Administration (HAHSTA)
DC Department of Health
899 N. Capitol St. NE
Fourth Floor
Washington, DC 20002

Phone: (202) 671-4900

This report is available online at: https://dchealth.dc.gov/service/hiv-reports-and-publications

Contents

Executive Summary 3
HIV Cases Living in DC 6
Newly Diagnosed HIV Cases 8
Perinatal HIV 9
HIV Incidence 9
HIV Care Dynamics 10
Ryan White Care Dynamics 12
Transmitted Drug Resistance 13
HIV Mortality 14
Sexually Transmitted Infections 15
Chlamydia 15
Gonorrhea 16
Syphilis 17
Viral Hepatitis 18
Hepatitis B 18
Hepatitis C 19
Tuberculosis 21
Focus Populations 22
Women 22
Men who have Sex with Men 23
People Who Inject Drugs (PWID) 24
Transgender People 25
Older Adults (Aged 55 and older) 26
Latinos 27
Youth (Aged 13-24) 28
Foreign-born 30
National HIV Behavioral Surveillance Study (NHBS) 31
Executive Summary

The Annual HIV, Sexually Transmitted Infections (STIs), Hepatitis, and Tuberculosis (TB) Surveillance Report for the District of Columbia shows the District continues to experience complex epidemics of HIV, STIs, hepatitis, and TB. The Department of Health (DC Health) reports that the number of new HIV cases decreased by the widest margin in the past five years, which is encouraging that efforts to accelerate key prevention and treatment strategies are proving effective. The District maintained high rates of STIs and a decrease in new TB cases. There are encouraging advances in more people being diagnosed and treated to cure for hepatitis C.

Figure 1. Newly Diagnosed HIV Disease Cases, Deaths, and Living HIV Cases, by Year, District of Columbia, 1983-2019.

Key points in this surveillance update of the District epidemics in the year 2019 include:

- 12,408 current residents of the District of Columbia or 1.8% of the population are living with HIV.
- The number of newly diagnosed HIV cases in the District decreased to 282 cases in 2019, a decline of 61% from 721 cases in 2011 and 79% from 1,374 cases in 2007.
- There were two babies born with HIV in 2019.
- The number of newly diagnosed HIV cases attributable to injection drug use decreased by 99% from 150 cases in 2007, prior to the scale up of DC’s needle exchange program, to 2 cases in 2019.
- Blacks and Latinos with HIV exceeded 1% of their respective populations, with Blacks disproportionately impacted at 2.8%.
- More than half of people living with HIV in DC are 50 years old and older.
- Young people ages 13 to 24 represent nearly 20% of new HIV diagnoses between 2015 and 2019; the number of new HIV diagnoses among young people ages 20-24 remained level for the past three years.
- Men who have sex with men and heterosexual contact are the two leading modes of transmission reported among newly diagnosed and identified HIV cases.
There were 9,337 cases of chlamydia, 4,374 cases of gonorrhea and 297 cases of primary and secondary syphilis reported in 2019.

A substantial minority (37%) of primary and secondary syphilis cases occurred among people with HIV, which declined from 43% in 2015.

There were 1,099 people with newly reported hepatitis C in 2019.

There were 24 cases of TB in 2019 with nearly three-quarters occurring among people born outside of the US.

HIV Care Continuum

DC Health tracks the District's efforts to improve the care continuum for people living with HIV to sustain their health from diagnosis to linkage and retention in care. The care continuum measures people linked to care, engaged in care, and viral load suppression. Surveillance data includes all people known to be living in the District. DC Health administers the Ryan White CARE Program that serves more than half of all people living with HIV in the District. People achieving viral suppression maintain strong immune systems, achieve healthier outcomes, and cannot transmit HIV sexually to other people, known as Undetectable equals Untransmittable or U=U. The District saw improvements in the HIV care continuum in DC through 2019:

- Among people newly diagnosed with HIV, 62% were linked to medical care within 7 days of diagnosis and 81% within 30 days.
- Viral suppression among all people living with HIV in DC remained at 69% overall and 87% among people with an indication of engagement in care.
- Among people newly diagnosed with HIV, 59% were virally suppressed within 90 days, which is an improvement from 45% in 2018. However, this indicates that not enough people are getting on HIV treatment timely to attain viral suppression.
- Of the 4,304 Ryan White clients with one or more medical visits, 95% were prescribed treatment and 84% were virally suppressed.
- Young people ages 0-19 and 20-24 had the lowest viral suppression rates at 31.4% and 54.6%, respectively; among newly diagnosed people, viral suppression rates within 12 months of diagnosis were lowest for people who inject drugs at 45.8%.
- There was a 50% increase in cardiovascular causes of death among people with HIV, which highlights that importance of holistic approaches to health, including smoking cessation.

Scaling Up Success

The District Government and its community partners continue to scale up programs to reduce the impact of HIV, STDs, hepatitis, and TB on residents of Washington, DC. These successes are the most recent achievements by the District.

- Supported about 1,700 people to start Pre-Exposure Prophylaxis (PrEP) in 2019.
- Distributed more than 4.6 million male and female condoms in 2019.
- Removed 478,038 needles from the street in 2019 through the DC needle exchange programs.
- Distributed 43,034 Naloxone kits, saved nearly 1,000 people from opioid overdose death, and supported 520 people onto medication assisted treatment for opioid addiction in 2019.
- Provided more than 5,000 STD tests for young people through the school-based STD screening and community screening programs in 2019.
- Provided HIV medical care and support services to more than 6,500 people through the Ryan White Program in 2019.

Ending the HIV Epidemic

In 2016, Mayor Bowser released the 90/90/90/50 Plan to End the HIV Epidemic in the District of Columbia by 2020.
While there has been steady progress (see Table E1), including meeting the first goal of the plan a year early, this year’s report reflects the necessity to increase availability, accessibility, and acceptability of services. In 2019, the US Department of Health and Human Services launched an Ending the HIV Epidemic Initiative, which focuses on 48 counties, seven rural states, and two cities (Washington, DC and San Juan, PR) where half of all new HIV diagnoses are located nationally. DC Health with its public-private collaborators DC Appleseed Center and Washington AIDS Partnership aims to update the 90/90/90/50 Plan to achieve a compatible and timely end to the epidemic in the nation’s capital.

Table 1. Mayor’s 90/90/90/50 Ending the HIV Epidemic Plan Goal Update, 2019

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Goal #1: 90% of HIV-positive District residents know their status</td>
<td>86%</td>
<td>86%</td>
<td>87%</td>
<td>88%</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>Goal #2: 90% of District Residents living with HIV are in treatment</td>
<td>73%</td>
<td>76%</td>
<td>77%</td>
<td>77%</td>
<td>80%</td>
<td>90%</td>
</tr>
<tr>
<td>Goal #3: 90% of District residents living with HIV who are in treatment reach viral suppression</td>
<td>78%</td>
<td>82%</td>
<td>84%</td>
<td>85%</td>
<td>87%</td>
<td>90%</td>
</tr>
<tr>
<td>Goal #4: 50% reduction in new HIV diagnoses</td>
<td>399</td>
<td>379</td>
<td>371</td>
<td>335</td>
<td>282</td>
<td>196</td>
</tr>
</tbody>
</table>
HIV Cases Living in DC

In 2016, this report, for the first time, devised a methodology to more accurately count the number of people diagnosed with HIV actually living in the District as compared to previous reports that contained data of the cumulative number of known living individuals diagnosed with HIV who were residents of the District at the time of diagnosis. The new methodology is repeated here. As presented in Figure 1, the number of all diagnosed stands at 17,781. Figure 1 accounts for new HIV diagnoses among current District residents, reported deaths among those previously diagnosed, and the residential migration of HIV positive individuals in and out of the District over time. The report uses residence at last lab to more accurately assess the number of individuals diagnosed with HIV living within the District (Figure 1). This methodology not only provides a better foundation for understanding the extent of HIV within the District, but also an improved baseline from which to evaluate the population coverage of HIV prevention and care activities.

Figure 2. People Living with HIV in the District of Columbia as of December 31, 2019

Estimation of the Number of People Living in DC

Of the 17,781 individuals diagnosed with HIV while a District resident, approximately 42% (n=7,520) were presumed to have moved outside of the jurisdiction (out-migration) prior to the end of 2019, as evidenced by a non-District residential address on their last reported laboratory report or the lack of any reported laboratory information for more than 5 years. Laboratory data was also used to assess the number of individuals diagnosed with HIV while a resident of other jurisdictions who have moved into the District over time (in-migration); we identified 2,147 individuals initially diagnosed with HIV outside of the jurisdiction with a current residential address in the District. As indicated in Figure 1, after adjusting the initial count of all living HIV cases for in- and out-migration, an estimated 12,408 individuals diagnosed with HIV were presumed to be living in the District at the end of 2019. Detailed characteristics of people living with HIV based on residential migration status since diagnosis are included in appendix tables B1-B4. In the future, HAHSTA expects to refine the estimates further, as a result of improved data-sharing processes with surrounding jurisdictions and additional information sources for ascertainment of residential addresses.
People Living with HIV

12,408

1.8%

3.3%

Number of DC’s population known to be living with HIV

Percent of DC’s population known to be living with HIV

Proportion of DC residents aged 50 and older living with HIV at the end of 2019

Proportion of HIV Cases Living in DC, by Race/Ethnicity, Gender Identity and Mode of Transmission, District of Columbia, 2019

Black MSM and MSM/IDU

Black Heterosexual Men

Black Men Other/RNI

Black Men IDU

Black Heterosexual Women

16%

White MSM and MSM/IDU

13%

Latino MSM and MSM/IDU

5%

Latino Male Other

1%

Latino Female: All modes of transmission; White Female: All modes of transmission; Other: All persons of other race with all modes of transmission; Transgender persons: Include both transgender man and transgender woman

Mann: includes men who have sex with men; IDU: Injection drug use; RNI: Risk not identified; Other: Perinatal transmission, hemophilia, blood transfusion, and occupational exposure

Non-Mann: All modes of transmission excluding MSM and MSM/IDU

Latino Male Other: Heterosexual, IDU, RNI and other modes of transmission; Black Male Other: RNI and other modes of transmission; Black Male Other: RNI and other modes of transmission; Latino Female: All modes of transmission; White Female: All modes of transmission; Other: All persons of other race with all modes of transmission; Transgender persons: Include both transgender man and transgender woman

Rate of HIV Cases Living in the District by Census Tract, District of Columbia, 2019 (N=12,408*)

Rate of HIV per 100,000 persons

0-795.4

795.5-1,523.1

1,523.2-2,172.5

2,172.6-2,974.2

2,974.3-4,378.4

Proportion of Residents Living with HIV by Race/Ethnicity and Gender Identity, District of Columbia, 2019

White Women 0.1%

Latino Women 0.3%

White Men 1.4%

Black Women 1.7%

Latino Men 2.1%

Black Men 4.0%

Rates were calculated using the 2018 Census Estimates

*5% of cases had a missing address or an address that did not geocode and were not included in this map. Though not included in this map, 51 cases were in jail and 79 cases were homeless.
Newly Diagnosed HIV Cases

Rate of Newly Diagnosed HIV Cases by Year of Diagnosis and Gender Identity, District of Columbia, 2015-2019

<table>
<thead>
<tr>
<th>Year of Diagnosis</th>
<th>Male</th>
<th>Female</th>
<th>Transgender</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>399</td>
<td>24.1%</td>
<td>3.0%</td>
</tr>
<tr>
<td>2016</td>
<td>379</td>
<td>24.8%</td>
<td>2.6%</td>
</tr>
<tr>
<td>2017</td>
<td>371</td>
<td>23.7%</td>
<td>2.2%</td>
</tr>
<tr>
<td>2018</td>
<td>335</td>
<td>21.2%</td>
<td>3.0%</td>
</tr>
<tr>
<td>2019</td>
<td>282</td>
<td>21.6%</td>
<td>2.5%</td>
</tr>
</tbody>
</table>

72.9% 72.6% 74.1% 75.8% 75.9%

Of those newly diagnosed with HIV in the District between 2015-2019

- 1 in 4 were Black Women
- 2 in 5 were men who have sex with men of color
- 1 in 3 were aged 20-29
- 1 in 7 Had at least 1 STI diagnosis within 12mo of HIV diagnosis

Proportion of Newly Diagnosed HIV Cases, by Race/Ethnicity, Gender Identity and Mode of Transmission, District of Columbia, 2015-2019, N=1,766

Black MSM and MSM/IDU 31%

<table>
<thead>
<tr>
<th>Black Heterosexual Men</th>
<th>Black Men Other/RNI</th>
<th>Black Women Other/RNI 5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>9%</td>
<td>7%</td>
<td>1%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Black Heterosexual Women</th>
<th>16%</th>
</tr>
</thead>
</table>

White MSM and MSM/IDU 9%

<table>
<thead>
<tr>
<th>Latino MSM and MSM/IDU</th>
<th>Latino Men Other 2%</th>
<th>Other 5%</th>
<th>Transgender persons 3%</th>
</tr>
</thead>
<tbody>
<tr>
<td>9%</td>
<td>1%</td>
<td>1%</td>
<td>5%</td>
</tr>
</tbody>
</table>

*6% of cases had a missing address or an address that did not geocode and were not included in this map. Though not included in this map, there was 1 homeless case and 11 cases diagnosed in jail.

Rates were calculated using the 2018 Census Estimates

Please refer to appendix table B5-B7 for additional data regarding newly diagnosed HIV cases.
Perinatal HIV

Perinatal HIV cases are defined as those in which transmission occurs during pregnancy, labor and delivery, or breastfeeding. Since the introduction of recommendations to provide anti-retroviral medication to women during pregnancy, during labor and delivery, and to the infant in the neonatal period, there has been a 95% reduction in mother to child transmission of HIV nationally. Transmission rates among those who receive recommended treatment during pregnancy, at labor and delivery, and newborn period are as low as 1%.

Figure 3. Perinatal HIV cases by Year of Birth, District of Columbia, 2007-2019

HIV Incidence

Figure 4. Estimated Number of Newly Infected HIV Cases by Year, District of Columbia, 2015-2019

The estimated number of new infections of HIV in the District remained stable from 2015 to 2019. The estimated rate of new infections in the District exceeded the national rate in 2018 at 46.5 estimated cases per 100,000 compared with 13.3 estimated cases per 100,000 respectively. Since the number of new infections of HIV is an estimate, the 95% confidence interval shows the range within which the estimate may be after adjusting for variability in sampling and timing of testing.
HIV Care Continuum

The HIV Care Continuum is the approach of diagnosing people with HIV, linking them into care and treatment, retaining them in care and medication adherence, and achieving viral load suppression, which is the marker of a person’s and community’s HIV health. Assessing HIV care dynamics is an essential step in understanding the strengths of HIV programs in the District, as well as an opportunity to identify and resolve gaps in the care continuum.

Figure 5. 2019 HIV Care Continuum among People Living with HIV in DC

Please refer to appendix table B8 for additional data regarding HIV care dynamics.
*Other race/ethnicity includes, Asian, Pacific Islander, Hawaii/Alaska Native, multi-race and missing
†IDU= Injecting drug user/People who inject drugs
** Other mode of HIV transmission includes pernatal, blood transfusion, healthcare exposure and blood transfusion
^RNI= Risk not identified

Please refer to appendix table B8-11 for additional data regarding HIV care dynamics.
Ryan White Program Care Continuum

HIV care metrics among Ryan White Program clients in the District were examined to evaluate clients on the care continuum. This continuum of care differs from what has been presented on the previous pages in several ways. First, the population used is a subset of the total number of HIV cases living in the District. These cases are not newly diagnosed in a given year, but these are HIV cases who received at least one Ryan White CARE Program-funded medical visit in 2019. Second, care status was measured through documented medical visits, rather than laboratory tests. Finally, information is included on the number of clients who were prescribed HIV treatment.

Table 2. Ryan White Care Continuum Measure Definitions

<table>
<thead>
<tr>
<th>Measure</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clients with one or more medical visit</td>
<td>Ryan White clients with at least one documented primary care visit in 2019</td>
</tr>
<tr>
<td>Retained in care in 2019</td>
<td>Having 2 or more medical visits in 2019 that were at least 90 days apart</td>
</tr>
<tr>
<td>Prescribed HAART</td>
<td>Ryan White clients with documentation of having been prescribed antiretroviral therapy (ART) to treat HIV.</td>
</tr>
<tr>
<td>Virally suppressed in 2019</td>
<td>Having a viral load result of &lt;200 copies/mL at the most recent viral load test in 2019</td>
</tr>
</tbody>
</table>

Figure 6. 2019 HIV Care Continuum among Ryan White Clients, District of Columbia

Please refer to appendix table B12 for additional data regarding the HIV Care Continuum among RW clients.
Transmitted Drug Resistance

Table 3. Evidence of Antiretroviral Drug Resistance among Newly Diagnosed HIV Cases with Initial Genotype Sequences Collected within 90 days of Diagnosis, District of Columbia, 2015-2019

<table>
<thead>
<tr>
<th>Antiretroviral Drug Classification</th>
<th>Antiretroviral Drug (ARV)</th>
<th>High-Level Resistance %</th>
<th>Intermediate Resistance %</th>
<th>Low-Level Resistance %</th>
<th>Susceptible %</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrase Strand Transfer Inhibitors</td>
<td>Bictegravir</td>
<td>0.0</td>
<td>0.5</td>
<td>0.0</td>
<td>99.5</td>
<td>209</td>
</tr>
<tr>
<td></td>
<td>Dolutegravir</td>
<td>0.0</td>
<td>0.5</td>
<td>0.0</td>
<td>99.5</td>
<td>209</td>
</tr>
<tr>
<td></td>
<td>Elvitegravir</td>
<td>1.0</td>
<td>0.0</td>
<td>2.4</td>
<td>96.6</td>
<td>209</td>
</tr>
<tr>
<td></td>
<td>Raltegravir</td>
<td>0.5</td>
<td>0.5</td>
<td>2.4</td>
<td>96.6</td>
<td>209</td>
</tr>
<tr>
<td>Non-Nucleotide Reverse Transcriptase Inhibitors</td>
<td>Doravirine</td>
<td>1.0</td>
<td>2.7</td>
<td>2.5</td>
<td>93.8</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Efavirenz</td>
<td>11.2</td>
<td>1.6</td>
<td>1.0</td>
<td>86.2</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Etravirine</td>
<td>0.9</td>
<td>1.3</td>
<td>0.9</td>
<td>97.0</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Nevirapine</td>
<td>12.0</td>
<td>1.8</td>
<td>0.8</td>
<td>85.5</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Rilpivirine</td>
<td>2.4</td>
<td>0.9</td>
<td>4.1</td>
<td>92.6</td>
<td>803</td>
</tr>
<tr>
<td>Nucleotide Reverse Transcriptase Inhibitors</td>
<td>Abacavir</td>
<td>1.1</td>
<td>0.3</td>
<td>3.0</td>
<td>95.6</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Didanosine</td>
<td>0.9</td>
<td>0.9</td>
<td>1.1</td>
<td>97.1</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Emtricitabine</td>
<td>3.4</td>
<td>0.0</td>
<td>0.0</td>
<td>96.6</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Lamivudine</td>
<td>3.4</td>
<td>0.0</td>
<td>0.0</td>
<td>96.6</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Stavudine</td>
<td>0.6</td>
<td>1.3</td>
<td>2.0</td>
<td>96.1</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Tenofovir</td>
<td>0.1</td>
<td>0.6</td>
<td>1.5</td>
<td>97.8</td>
<td>803</td>
</tr>
<tr>
<td></td>
<td>Zidovudine</td>
<td>0.5</td>
<td>1.3</td>
<td>1.1</td>
<td>97.1</td>
<td>803</td>
</tr>
<tr>
<td>Protease Inhibitors</td>
<td>Atazanavir/r</td>
<td>0.4</td>
<td>0.1</td>
<td>0.9</td>
<td>98.7</td>
<td>815</td>
</tr>
<tr>
<td></td>
<td>Darunavir/r</td>
<td>0.3</td>
<td>0.3</td>
<td>0.0</td>
<td>99.4</td>
<td>815</td>
</tr>
<tr>
<td></td>
<td>Fosamprenavir/r</td>
<td>0.4</td>
<td>0.4</td>
<td>0.7</td>
<td>98.5</td>
<td>815</td>
</tr>
<tr>
<td></td>
<td>Indinavir/r</td>
<td>0.3</td>
<td>0.6</td>
<td>0.5</td>
<td>98.7</td>
<td>815</td>
</tr>
<tr>
<td></td>
<td>Lopinavir/r</td>
<td>0.1</td>
<td>0.5</td>
<td>0.6</td>
<td>98.8</td>
<td>815</td>
</tr>
<tr>
<td></td>
<td>Nelfinavir</td>
<td>0.2</td>
<td>0.3</td>
<td>1.0</td>
<td>97.6</td>
<td>815</td>
</tr>
<tr>
<td></td>
<td>Saquinavir/r</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
<td>98.8</td>
<td>815</td>
</tr>
<tr>
<td></td>
<td>Tipranavir/r</td>
<td>0.3</td>
<td>0.6</td>
<td>0.0</td>
<td>99.1</td>
<td>815</td>
</tr>
</tbody>
</table>

Antiretroviral drug resistance is an important guide to medical providers in determining the best treatment regimen for a person newly diagnosed with HIV. The genotype test gives the drug resistance profile of the particular type of virus the person has and if there are medications that will not be effective with the virus. HIV can become resistant to some medications, usually when a person does not consistently take their medication. While current treatment guidelines* specify that a genotypic resistance test should be conducted at the time of HIV diagnosis prior to starting antiretroviral therapy, only 55.3% of new HIV cases diagnosed in 2019 had a reported genotype test sequence** within 3 months of diagnosis. Ensuring that newly diagnosed HIV cases receive genotypic resistance testing is not only important for clinical practice, but is also essential for monitoring trends in drug resistance at the population level.
The dominant subtype among cases in DC is subtype B, which accounts for 90.6% of available genotype sequences. The largest proportions of high level resistance were found for Nevirapine (12.0%) and Efavirenz (11.2%). The smallest proportions of resistance were found in the protease inhibitors drug class with resistance ranging from 0%-1.0%. Additional information about drug resistance can be found in Appendix A under *Understanding HIV-related Drug Resistance.*


** Genotype sequences are reported via HL7 messages to the DC Department of Health.

## HIV Mortality

**Table 4. Primary Cause of Death among People Diagnosed with HIV, by Year of Death, District of Columbia, 2014-2018**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-related causes</td>
<td>73</td>
<td>26.5</td>
<td>NA</td>
<td>NA</td>
<td>91</td>
<td>29.0</td>
<td>86</td>
<td>28.3</td>
<td>87</td>
<td>31.4</td>
<td>337</td>
<td>28.8</td>
</tr>
<tr>
<td>Non-AIDS Defining</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignancies</td>
<td>45</td>
<td>16.4</td>
<td>NA</td>
<td>NA</td>
<td>47</td>
<td>15.0</td>
<td>50</td>
<td>16.4</td>
<td>37</td>
<td>13.4</td>
<td>179</td>
<td>15.3</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>45</td>
<td>16.4</td>
<td>NA</td>
<td>NA</td>
<td>46</td>
<td>14.6</td>
<td>58</td>
<td>19.1</td>
<td>68</td>
<td>24.5</td>
<td>217</td>
<td>18.5</td>
</tr>
<tr>
<td>Substance Use</td>
<td>3</td>
<td>1.1</td>
<td>NA</td>
<td>NA</td>
<td>3</td>
<td>1.0</td>
<td>2</td>
<td>0.7</td>
<td>3</td>
<td>1.1</td>
<td>15</td>
<td>1.3</td>
</tr>
<tr>
<td>Accidental Death</td>
<td>20</td>
<td>7.3</td>
<td>NA</td>
<td>NA</td>
<td>38</td>
<td>12.1</td>
<td>38</td>
<td>12.5</td>
<td>28</td>
<td>10.1</td>
<td>124</td>
<td>10.6</td>
</tr>
<tr>
<td>Other*</td>
<td>53</td>
<td>19.3</td>
<td>NA</td>
<td>NA</td>
<td>62</td>
<td>19.7</td>
<td>47</td>
<td>15.5</td>
<td>44</td>
<td>15.9</td>
<td>206</td>
<td>17.6</td>
</tr>
<tr>
<td>Unknown</td>
<td>36</td>
<td>13.1</td>
<td>NA</td>
<td>NA</td>
<td>27</td>
<td>8.6</td>
<td>23</td>
<td>7.6</td>
<td>10</td>
<td>3.6</td>
<td>96</td>
<td>8.2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>275</strong></td>
<td><strong>100.0</strong></td>
<td><strong>NA</strong></td>
<td><strong>NA</strong></td>
<td><strong>314</strong></td>
<td><strong>100.0</strong></td>
<td><strong>304</strong></td>
<td><strong>100.0</strong></td>
<td><strong>277</strong></td>
<td><strong>100.0</strong></td>
<td><strong>1,170</strong></td>
<td><strong>100.0</strong></td>
</tr>
</tbody>
</table>

†2015 cause of death is incomplete and will be updated when available.

* Other causes of death include suicide, pneumonia, chronic obstructive pulmonary disorder (COPD), diabetes, etc.

Over 70% of deaths among people diagnosed with HIV in the District were due to non-HIV related causes between 2014 and 2018. People diagnosed with HIV who died in 2015 had an incomplete cause of death and were not included in this report.

Please refer to appendix table B13 for additional data regarding deaths among people diagnosed with HIV disease.
Sexually Transmitted Infections

Chlamydia

Number of diagnoses reported in 2019

- 9,337 cases

- 5.4% of DC residents aged 18-19 acquired Chlamydia in 2019

- 4% of people diagnosed with Chlamydia in 2019 were living with HIV

- 16% of DC residents diagnosed with Chlamydia in 2019 had an STI in the previous year

Rate of Newly Reported Chlamydia Diagnoses, by Census Tract, District of Columbia, 2019

(N=9,337)

Newly Reported Diagnoses of Chlamydia, by Year, District of Columbia, 2015-2019

- 26% increase in cases from 2015 to 2019

- 1 in 5 were aged 13-19
- 1 in 2 were aged 20-29

Rates were calculated using the 2018 Census Estimates

Please refer to appendix table B14 for additional data regarding newly diagnosed Chlamydia cases.
Gonorrhea

Rates were calculated using the 2018 Census Estimates

Please refer to appendix table B15 for additional data regarding newly diagnosed Gonorrhea cases.
Syphilis

Number of primary or secondary Syphilis diagnoses reported in 2019

37% of people diagnosed with Syphilis were living with HIV

49% of people diagnosed with Syphilis in 2019 had another STI within the past year

1 the number of congenital cases diagnosed in 2019

Rate of Reported Primary and Secondary Syphilis Diagnoses, by Census Tract, District of Columbia, 2019 (N=297*)

Newly Reported Diagnoses of Primary and Secondary Syphilis, by Year, District of Columbia, 2015-2019

0 5 10 15 20 25 30 35
Newly Reported Cases

2015 2016 2017 2018 2019

Primary Syphilis Secondary Syphilis

115 68% 66% 67% 64% 63%

68% 32% 33% 36% 37%

Of those newly reported with Primary and Secondary Syphilis in DC in 2019...

9 in 10 were Men

1 in 2 were Black

1 in 4 were aged 30-39

2 in 3 were men who have sex with men

*5% of cases had a missing address or an address that did not geocode and were not included in this map

Rates were calculated using the 2018 Census Estimates

Please refer to appendix table B16 for additional data regarding newly diagnosed syphilis cases.
Viral Hepatitis

Hepatitis B

1,750

Number of newly reported chronic Hepatitis B cases between 2015-2019

42.9

Rate of Chronic Hepatitis B in 2019 per 100,000 persons

Of all reported Chronic Hepatitis B Cases in DC between 2015-2019...

2 in 3 were Men

1 in 5 were aged 30-39

Newly Reported Chronic Hepatitis B Cases by Year, District of Columbia, 2015-2019, N=1,750

2015: 362 cases
2016: 384 cases
2017: 297 cases
2018: 406 cases
2019: 301 cases

Distribution of Newly Diagnosed Chronic HBV Cases by Age at Diagnosis, District of Columbia 2015-2019 N=1,750

- 20.5% ≤12
- 20.2% 13-19
- 19.7% 20-29
- 12.1% 30-39
- 25.4% 40-49
- 0.1% 50-59
- 0.4% ≥60
- 1.6% Unknown

Please refer to appendix table B18 for additional data regarding diagnosed Hepatitis B cases.
Hepatitis C

15,811

Number of all positive chronic Hepatitis C cases between 2015-2019

6,671

Number of newly reported chronic Hepatitis C cases between 2015-2019

Of all reported Chronic Hepatitis C cases in DC between 2015-2019...

2 in 3 were Men

3 in 4 were aged 50 and older

2 in 3 were born between 1945 and 1965

Newly Reported Chronic HCV Cases by Birth Cohort and Year of Diagnosis, District of Columbia, 2015-2019, N=6,671

Newly Reported Chronic Hepatitis C Cases by Year, District of Columbia, 2015-2019, N=6,671

Distribution of All* Reported Chronic HCV Cases by Current Age, District of Columbia 2015-2019

N=15,811

* includes both newly and previously diagnosed cases with a reported positive HCV test between 2015 and 2019

Please refer to appendix table B19-20 for additional data regarding diagnosed Hepatitis C cases.
Chronic Hepatitis C Cure Cascade

While hepatitis surveillance and case investigation activities are currently limited, efforts have been made toward utilizing available data and resources to better understand care and treatment dynamics among individuals diagnosed with chronic hepatitis C (HCV). Based on current surveillance data, 76% of individuals reported to DC Health as having chronic HCV between 2015 and 2019 had a documented positive HCV RNA confirmatory test. Of those having a positive HCV confirmatory test, 24% had evidence of an undetectable viral load based on the last reported HCV RNA laboratory result. Both percentage points provide preliminary evidence that there are opportunities to enhance care linkage and engagement activities within the District in relation to addressing the treatment needs of people with chronic HCV.

Figure 7. HCV Cure Cascade, District of Columbia 2015-2019
Tuberculosis

Tuberculosis (TB) is caused by the bacteria Mycobacterium tuberculosis. TB is spread from person to person through the air where infection can occur by sharing airspace for an extended period of time in an enclosed setting such as one’s home or in a small office. TB usually affects the lungs, and bacteria are put into the air when a person with active TB of the lungs coughs, sneezes, laughs, or sings. TB can also affect other parts of the body (extrapulmonary TB). TB can be cured if treated properly.

Number of TB cases diagnosed between 2015-2019: 154
Number of new TB diagnoses in DC in 2019: 24
Multidrug-resistant TB cases in 2019: 0
Proportion of diagnoses that co-occurred with HIV: 4.1%

Of those newly diagnosed with Tuberculosis in the District between 2015-2019:
- 2 in 3 were foreign-born
- 2 in 5 were aged 25-44

Proportion of Newly Diagnosed TB Cases, by Age at Diagnosis, District of Columbia, 2015-2019, N=154

Please refer to appendix table B17 for additional data regarding newly diagnosed TB cases.
Focus Populations

Women

Number of Women in DC known to be living with HIV
3,292

Number of new HIV diagnoses in DC in 2019
61

Percent of women living in DC known to be living with HIV
0.9%

Proportion of women living in DC with a chlamydia diagnosis in 2019
1.3%

Number of HIV positive women who gave birth in 2019
43

HIV Care Continuum among Women Diagnosed with HIV Living in DC, 2019

- Living in DC Ever linked to HIV care: 3,233
- Retained in any care in 2019: 3,096
- 81% at least 1 medical visit: 2,261
- 69% suppressed: 2,243

Stage of HIV at First Lab in DC and in 2019 among Women Living in DC, District of Columbia, N=3,233

- 4% First stage in DC
- 30% Stage 2
- 32% Stage 3
- 34% Not reported
- 15% Stage in 2019
- 7% Stage 2
- 20% Stage 3
- 54% Not reported

*Treatment guidelines do not require annual CD4 counts to be drawn if a person is virally suppressed in 2019.

Of those women newly diagnosed with HIV in DC in 2019...

- 9 in 10 were Black
- 3 in 10 were aged 50-59

Number of Newly Reported HIV cases among Women, by Year, District of Columbia, 2015-2019

Number of Reported Chlamydia and Gonorrhea Infections

- HIV disease
- Chlamydia
- Gonorrhea
Men who have Sex with Men

Number of Men who have sex with men in DC known to be living with HIV

5,621

12%

Proportion of new HIV diagnoses in 2019 with a mode of transmission of MSM among those aged 13-24

Number of New Reported HIV and Syphilis among Men who have Sex with Men, by Year, District of Columbia, 2015-2019

HIV Care Continuum among MSM Diagnosed with HIV Living in DC, 2019

Living in DC in 2018: 5,980
Ever linked to HIV care: 5,905
99% ever linked
Retained in any care in 2019: 4,372
73% at least 1 medical visit
Virally suppressed in 2019: 4,249
71% suppressed

Stage of HIV at First Lab in DC and in 2019 among MSM Living in DC, District of Columbia, N=6,112

Of those newly diagnosed MSM with HIV in DC in 2019...

1 in 2 were Black
1 in 4 were White
1 in 3 were aged 30-39

*Treatment guidelines do not require annual CD4 counts to be drawn if a person is virally suppressed in 2019.
## People who Inject Drugs (PWID)

| Number of PWID in DC known to be living with HIV in 2019 | 1,159 |
| Number of new HIV diagnoses in DC in 2019 | 2 |
| Proportion of HIV/HCV co-occurrence among PWID living in DC in 2019 | 27% |

### HIV Care Continuum among PWID Diagnosed with HIV Living in DC, 2019

- Living in DC in 2018: 1,159
- Ever linked to HIV care: 1,146
- Retained in any care in 2019: 998
- 86% at least 1 medical visit
- Virally suppressed in 2019: 840
- 99% ever linked
- 73% suppressed

### Newly Diagnosed PWID and the Number of Needles Exchanged, by Year, District of Columbia, 2008-2019

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of Newly Diagnosed HIV Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>140</td>
</tr>
<tr>
<td>2009</td>
<td>100</td>
</tr>
<tr>
<td>2010</td>
<td>80</td>
</tr>
<tr>
<td>2011</td>
<td>60</td>
</tr>
<tr>
<td>2012</td>
<td>40</td>
</tr>
<tr>
<td>2013</td>
<td>20</td>
</tr>
<tr>
<td>2014</td>
<td>10</td>
</tr>
<tr>
<td>2015</td>
<td>5</td>
</tr>
<tr>
<td>2016</td>
<td>2</td>
</tr>
<tr>
<td>2017</td>
<td>1</td>
</tr>
<tr>
<td>2018</td>
<td>0</td>
</tr>
<tr>
<td>2019</td>
<td>0</td>
</tr>
</tbody>
</table>

- **New IDU Diagnosed**: Orange
- **Needles Distributed**: Blue

### Stage of HIV at First Lab in DC and in 2019 among PWID Living in DC, District of Columbia, N=1,159

- **First Stage in DC**
  - Stage 1: 26%
  - Stage 2: 44%
  - Stage 3: 29%

- **Stage in 2019**
  - Stage 1: 49%
  - Stage 2: 27%
  - Stage 3: 15%
  - Not Reported: 10%

*Treatment guidelines do not require annual CD4 counts to be drawn if a person is virally suppressed in 2019.
Transgender People

Number of transgender individuals in DC known to be living with HIV in 2019: 253
Number of transgender individuals newly diagnosed between 2015-2019: 48
Proportion of new diagnoses that were aged 25-29 between 2015-2019: 32%

Stage of HIV at First Lab in DC and in 2019 among Transgender People Living in DC, District of Columbia, N=241
- 3% Living in DC in 2018
- 31% Ever linked to HIV care
- 24% Retained in any care in 2019
- 33% Virally suppressed in 2019
- 5% 97% ever linked
- 20% 78% at least 1 medical visit

Number of New HIV Diagnoses among Transgender People, by Year, District of Columbia, 2015-2019, N=48
- 2015: 12
- 2016: 10
- 2017: 8
- 2018: 10
- 2019: 8

*Treatment guidelines do not require annual CD4 counts to be drawn if a person is virally suppressed in 2019.
Older Adults (Aged 55 and older)

Number of individuals aged 55+ known to be living with HIV: 4,682
Number of new HIV diagnoses in DC in 2019: 37

Stage of HIV at First Lab in DC and in 2019
Among People aged 55+ Living in DC, District of Columbia, N=4,331

- First stage in DC: 2%
- Stage 2: 42%
- Stage 3: 28%
- Not reported: 29%

- Stage 2019: 21%
- 6%
- 24%
- 49%

HIV Care Continuum among Persons Aged 55+
Diagnosed with HIV Living in DC, 2019

- Living in DC in 2018: 4,331
- Ever linked to HIV care: 4,255 (98% ever linked)
- Retained in any care in 2019: 3,542 (82% at least 1 medical visit)
- Virally suppressed in 2019: 3,223 (70%)

Number of Newly Reported HIV, Chlamydia, Gonorrhea and P&S Syphilis Diagnoses among People aged 55+, by Year, District of Columbia, 2015-2019

- Of those newly diagnosed with HIV in DC in 2015-2019...
  - 4 in 5 were Black
  - 3 in 5 were men
  - 2 in 3 had a mode of transmission of sexual contact

- HIV disease: 65 78 70 55 47 37
- Chlamydia: 60 108 108 120 136 146
- Gonorrhea: 90 129 129 130 132 134
- Syphilis: 55 48 48 53 53
Latinos

Number of Latinos in DC known to be living with HIV: 973 (1.2%)

Care Continuum among Latinos Diagnosed with HIV and Living in DC, 2019:
- 934 Living in DC
- 898 Ever linked to HIV care
- 686 Retained in any care in 2019
- 613 Virally suppressed in 2019

Stage of HIV Disease at First Lab in DC and in 2019 among Latinos Living in DC, District of Columbia, N=934:
- First Stage in DC:
  - 4% Stage 1
  - 28% Stage 2
  - 36% Stage 3
  - 32% Not Reported
- Stage in 2019:
  - 4% Stage 1
  - 36% Stage 2
  - 16% Stage 3
  - 43% Not Reported

*Treatment guidelines do not require annual CD4 counts to be drawn if a person is virally suppressed in 2019.

Of those newly diagnosed with HIV in DC in 2015-2019:
- 8 in 10 Were Men who have Sex with Men
- 4 in 10 Were aged 20-29

Number of Newly Diagnosed Cases among Latinos, by Year and Gender Identity, District of Columbia, 2015-2019:
- 59 in 2015
- 42 in 2016
- 47 in 2017
- 31 in 2018
- 37 in 2019

Male: 88%, 88%, 89%, 87%, 78%
Female: 5%, 7%, 9%, 6%, 16%
Transgender: 12%, 4%, 2%, 6%, 5%
Youth (Aged 13-24)

Number of youth in DC known to be living with HIV in 2019: 274

HIV prevalence of youth living in DC in 2019: 0.3%

Incidence of Chlamydia among youth in 2019: 4.7%

Incidence of Gonorrhea among youth in 2019: 1.4%

Stage of HIV at First Lab in DC and in 2019 among Youth Living in DC, by Age Group, District of Columbia:

- Living in DC in 2018: 4% Stages 1, 6% Stages 2, 9% Stages 3, 31% Not Reported
- Ever linked to HIV care: 21% Stages 1, 44% Stages 2, 15% Stages 3, 57% Not Reported
- Retained in care in 2019: 10% Stages 1, 31% Stages 2, 10% Stages 3, 15% Not Reported
- Virally suppressed in 2019: 31% Stages 1, 15% Stages 2, 9% Stages 3, 48% Not Reported

HIV Care Continuum among Youth Aged 13-19 Diagnosed with HIV Living in DC, 2019:
- Living in DC in 2018: 47
- Ever linked to HIV care: 45 (95% ever linked)
- Retained in care in 2019: 42 (89% at least 1 medical visit)
- Virally suppressed in 2019: 30 (64% suppressed)

HIV Care Continuum among Youth Aged 20-24 Diagnosed with HIV Living in DC, 2019:
- Living in DC in 2018: 271
- Ever linked to HIV care: 250 (92% ever linked)
- Retained in care in 2019: 189 (70% at least 1 medical visit)
- Virally suppressed in 2019: 148 (55% suppressed)

Of those newly diagnosed with HIV in DC in 2019...

- 3 in 4 were Black
- 4 in 5 were among men who have sex with men
- 4 in 5 were aged 20-24
- 9 in 10 were male
Foreign-born

Number of foreign-born people living with HIV in DC at the end of 2019: 1,007
Number of foreign-born people newly diagnosed with HIV between 2015-2019: 289

Of all foreign-born Persons diagnosed in DC in 2019:
- 1 in 2 were Black
- 4 in 10 were aged 30-39
- 7 in 10 were Men

Stage of HIV at First Lab in DC and in 2019 among Foreign-born People Living in DC, District of Columbia, N=971

HIV Care Continuum among Foreign-born People Diagnosed with HIV living in DC, 2019

*Treatment guidelines do not require annual CD4 counts to be drawn if a person is virally suppressed in 2019.
National HIV Behavioral Surveillance Study (NHBS)

People who Inject Drugs

The National HIV Behavioral Surveillance (NHBS) is a CDC-funded initiative to learn more about what puts people at risk for HIV. The purpose of NHBS is to assess prevalence of HIV and trends in sexual and drug-use behaviors among populations most at risk for HIV. In 2018, people who inject drugs were recruited throughout the DC Metropolitan Statistical Area (MSA) and were surveyed.